These two top pot stocks will probably continue to struggle in the fourth quarter.
The market isn't pleased with its latest clinical update.
These two penny marijuana stocks may be worth adding to your portfolio right now.
AbbVie and Eli Lilly have both stumbled this year. Which of these top pharma stocks is better positioned for a rebound?
Here's why Catalyst's shareholder might want to simply shrug off yesterday's downturn.
Catalyst's latest bout of volatility could be a great buying opportunity for risk-tolerant investors.
A bet on this Canadian marijuana company is a bet on the political future of the country south of its home market.
These three biotech stocks could be great buys this month.
Acadia's stock has taken flight this year.
Investor concerns over the competitive outlook for the company's Pompe disease therapy candidate weighed on its stock price.
Amgen's best-selling medicine is safe from biosimilar competition for now.
Dynavax's stock surged higher in August. Can this small-cap biotech keep churning higher?
Acadia's flagship drug notched a key late-stage win today.
Biotech stocks tend to react badly to advisory committee meetings.
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
Retrophin's PKAN drug candidate missed the mark in a late-stage trial.
These three health care stocks deserve your undivided attention right now.
These three diabetes-oriented companies should be on your radar right now.
A surprise rejection is weighing on Sarepta's shares today.